Search Results - "Reder, Anthony T."
-
1
Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models
Published in The Journal of clinical investigation (01-05-2023)“…Multiple sclerosis (MS) is an inflammatory disease of the CNS. In this issue of the JCI, Ma and Sannino et al. show that two strains of intestinal Clostridium…”
Get full text
Journal Article -
2
Vitamin D and Multiple Sclerosis: A Comprehensive Review
Published in Neurology and therapy (01-06-2018)“…Numerous observational studies have suggested that there is a correlation between the level of serum vitamin D and MS risk and disease activity. To explore…”
Get full text
Journal Article -
3
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Published in Lancet neurology (01-06-2014)“…Summary Background Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further…”
Get full text
Journal Article -
4
Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-β-1a Compared to Non-PEGylated IFN-β-1a
Published in Journal of interferon & cytokine research (01-03-2023)“…Interferon (IFN)-β-1a (Avonex) and longer half-life, polyethylene glycol-conjugated IFN-β-1a (PEG-IFN-β-1a, Plegridy), may generate different molecular…”
Get more information
Journal Article -
5
How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms
Published in Journal of interferon & cytokine research (01-08-2014)“…Type I interferons (IFNs) are important in innate and adaptive immunity. They are used to treat virus infections, cancer, and multiple sclerosis (MS). There…”
Get more information
Journal Article -
6
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis
Published in Ophthalmology (Rochester, Minn.) (01-07-2013)“…Purpose To report outcomes of ophthalmic evaluations in clinical studies of patients receiving fingolimod (Gilenya; Novartis Pharma AG, Basel, Switzerland) for…”
Get full text
Journal Article -
7
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial
Published in Lancet neurology (01-01-2016)“…Summary Background Relapses of multiple sclerosis decrease during pregnancy, when the hormone estriol is increased. Estriol treatment is anti-inflammatory and…”
Get full text
Journal Article -
8
Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection
Published in EBioMedicine (01-11-2019)“…In multiple sclerosis (MS), immune up-regulation is coupled to subnormal immune response to interferon-β (IFN-β) and low serum IFN-β levels. The relationship…”
Get full text
Journal Article -
9
Immunomodulatory activity of interferon‐beta
Published in Annals of clinical and translational neurology (01-08-2014)“…Multiple sclerosis (MS) is a complex disorder of the central nervous system that appears to be driven by a shift in immune functioning toward excess…”
Get full text
Journal Article -
10
Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients
Published in Frontiers in immunology (05-05-2023)“…People identified with Black/African American or Hispanic/Latinx ethnicity are more likely to exhibit a more severe multiple sclerosis disease course relative…”
Get full text
Journal Article -
11
Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles
Published in Frontiers in neurology (24-04-2023)“…Anti-CD20 is a highly effective therapy for multiple sclerosis (MS), a disease with multiple abnormalities in function of B and T cells and innate immune…”
Get full text
Journal Article -
12
Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles
Published in Frontiers in neurology (08-08-2023)“…[This corrects the article DOI: 10.3389/fneur.2023.1158487.]…”
Get full text
Journal Article -
13
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
Published in Lancet neurology (01-07-2010)“…Summary The identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important. For…”
Get full text
Journal Article -
14
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment
Published in PloS one (21-12-2018)“…Brain volume loss is an important surrogate marker for assessing disability in MS; however, contribution of gray and white matter to the whole brain volume…”
Get full text
Journal Article -
15
Aberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body Ecology
Published in Frontiers in immunology (17-09-2013)“…Studying the action of mechanisms of type I interferon (IFN) provides the insight to elucidate the cause and therapy for autoimmune diseases. There are high…”
Get full text
Journal Article -
16
Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy
Published in Epilepsy & behavior (01-02-2014)“…Abstract Epilepsy is a chronic neurological disorder that results in recurring seizures and can have a significant adverse effect on health-related quality of…”
Get full text
Journal Article -
17
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
Published in Neurology and therapy (01-04-2024)“…Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central nervous system. Relapsing–remitting MS (RRMS), the most common form of…”
Get full text
Journal Article -
18
Therapeutic role of beta-interferons in multiple sclerosis
Published in Pharmacology & therapeutics (Oxford) (01-04-2006)“…Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS). In the last 12 years, there has been a proliferation of studies…”
Get full text
Journal Article -
19
Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS
Published in PloS one (30-11-2011)“…Establishing the long-term benefit of therapy in chronic diseases has been challenging. Long-term studies require non-randomized designs and, thus, are often…”
Get full text
Journal Article -
20
Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS
Published in Multiple sclerosis (01-06-2021)“…Thoracic flexion, a rapid forward flexion at the waist, can elicit a circumferential electrical sensation in some patients with multiple sclerosis. The…”
Get full text
Journal Article